![PDF) Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial PDF) Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial](https://i1.rgstatic.net/publication/339128346_Rationale_and_protocol_of_the_Dapagliflozin_And_Prevention_of_Adverse_outcomes_in_Chronic_Kidney_Disease_DAPA-CKD_randomized_controlled_trial/links/5e66b306a6fdcc37dd15c5e5/largepreview.png)
PDF) Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
![PDF) Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis PDF) Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis](https://i1.rgstatic.net/publication/349516607_Kidney_Cardiovascular_and_Safety_Outcomes_of_Canagliflozin_according_to_Baseline_Albuminuria_A_CREDENCE_Secondary_Analysis/links/60b4a3fca6fdcc1c66f4b4b6/largepreview.png)
PDF) Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis
![PDF) Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials PDF) Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials](https://i1.rgstatic.net/publication/373120178_Estimated_lifetime_benefit_of_novel_pharmacological_therapies_in_patients_with_type_2_diabetes_and_chronic_kidney_disease_A_joint_analysis_of_randomized_controlled_clinical_trials/links/653e81710426ef6369e9fb84/largepreview.png)
PDF) Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials
![Eligible Cohort of Patients With Diabetes Mellitus and ASCVD; Overall... | Download Scientific Diagram Eligible Cohort of Patients With Diabetes Mellitus and ASCVD; Overall... | Download Scientific Diagram](https://www.researchgate.net/publication/348423361/figure/tbl1/AS:1003117063729156@1616173153634/Eligible-Cohort-of-Patients-With-Diabetes-Mellitus-and-ASCVD-Overall-and-by-Therapy.png)
Eligible Cohort of Patients With Diabetes Mellitus and ASCVD; Overall... | Download Scientific Diagram
![PDF) Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial PDF) Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial](https://i1.rgstatic.net/publication/362506726_Effect_of_Canagliflozin_on_Total_Cardiovascular_Burden_in_Patients_With_Diabetes_and_Chronic_Kidney_Disease_A_Post_Hoc_Analysis_From_the_CREDENCE_Trial/links/62f81b41c6f6732999cbca0f/largepreview.png)
PDF) Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
![PDF) Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial PDF) Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial](https://i1.rgstatic.net/publication/350941425_Effects_of_dapagliflozin_on_mortality_in_patients_with_chronic_kidney_disease_a_pre-specified_analysis_from_the_DAPA-CKD_randomized_controlled_trial/links/607a8480907dcf667ba46201/largepreview.png)
PDF) Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
![PDF) A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function PDF) A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function](https://i1.rgstatic.net/publication/354759637_A_pre-specified_analysis_of_the_Dapagliflozin_and_Prevention_of_Adverse_Outcomes_in_Chronic_Kidney_Disease_DAPA-CKD_randomized_controlled_trial_on_the_incidence_of_abrupt_declines_in_kidney_function/links/614b39a7a3df59440ba46914/largepreview.png)
PDF) A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function
![يوسف الخاطر™🎭 on X: "أين تذهب صدقاتكم و زكواتكم يا تجار الكويت‼️ والله لتسألن عن هذا الشاب. http://t.co/20iPb0TTha" / X يوسف الخاطر™🎭 on X: "أين تذهب صدقاتكم و زكواتكم يا تجار الكويت‼️ والله لتسألن عن هذا الشاب. http://t.co/20iPb0TTha" / X](https://pbs.twimg.com/media/CFdHc8LVIAAbCDQ.jpg)